推進生命科學研發：SLAS發現報告了科學家如何開發和利用新技術和/或方法來提供和描述理解和治療人類疾病的化學和生物工具。SLAS Discovery是一個同行評審的期刊，它發布科學報告，以實現和改進目標驗證，評估當前的藥物發現技術，提供新穎的研究工具，并結合研究方法，提高知識深度和藥物發現的成功率。SLAS發現強調了目標識別/驗證（包括化學探針、RNA沉默、基因編輯技術）的科學和技術進步；生物標志物發現；分析開發；虛擬、中或高通量篩選（生化和生物、生物物理、表型、毒理學、ADME）；鉛生成/光學數字化；化學生物學；信息學（數據分析、圖像分析、統計學、生物和化學信息學）。綜述目標生物學、藥物發現的新范式和藥物發現技術的進展。SLAS的發現對分析化學、應用微生物學、自動化、生物化學、生物工程、生物醫學光學、生物技術、生物信息學、細胞生物學、DNA科學與技術、遺傳學、信息技術、醫學化學、分子生物學、天然產物化學、有機物等領域的研究者特別感興趣。化學、藥理學、光譜學和毒理學。SLAS Discovery是出版倫理委員會（COPE）的成員，之前（1996-2016年）作為生物分子篩選雜志（JBS）出版。

Advancing Life Sciences R&D: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease.SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success.SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies.SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology.SLAS Discovery is a member of the Committee on Publication Ethics (COPE) and was published previously (1996-2016) as the Journal of Biomolecular Screening (JBS).